RIGL vs. IAS

Last updated Jun 3, 2026

RIGL (Rigel Pharmaceuticals, Inc.) and IAS (Integral Ad Science Holding Corp.) are both stocks. RIGL operates in Biotechnology (Healthcare), while IAS operates in Advertising Agencies (Communication Services). At a 0.23 correlation, their price movements are largely independent.

Performance

RIGL vs. IAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rigel Pharmaceuticals, Inc. (RIGL) and Integral Ad Science Holding Corp. (IAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RIGL

• 1D: 0.54%
• 1M: 2.11%
• YTD: -29.91%
• 6M: -32.40%
• 1Y: 48.98%
• 3Y*: 28.95%
• 5Y*: -4.61%
• 10Y*: 1.65%

IAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RIGL vs. IAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RIGL Rigel Pharmaceuticals, Inc.	-29.91%	154.64%	16.00%	-3.33%	-43.40%	-38.94%
IAS Integral Ad Science Holding Corp.	0.00%	-0.96%	-27.45%	63.71%	-60.42%	7.92%

Correlation

The correlation between RIGL and IAS is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.08
Correlation (3Y) Calculated over the trailing 3-year period	0.21
Correlation (All Time) Calculated using the full available price history since Jul 1, 2021	0.23

The correlation between RIGL and IAS shifts across timeframes, from 0.08 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap RIGL : $590.97M IAS : $1.76B
EPS RIGL : $19.21 IAS : $0.28
PE Ratio RIGL : 1.56 IAS : 37.31
PEG Ratio RIGL : 0.00 IAS : 0.22
PS Ratio RIGL : 1.90 IAS : 2.95
PB Ratio RIGL : 1.48 IAS : 1.59
Total Revenue (TTM) RIGL : $299.77M IAS : $590.67M
Gross Profit (TTM) RIGL : $279.95M IAS : $457.31M
EBITDA (TTM) RIGL : $125.80M IAS : $119.85M

Return for Risk

RIGL vs. IAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RIGL

RIGL Risk / Return Rank: 63
RIGL Sharpe Ratio Rank: 63
RIGL Sortino Ratio Rank: 66
RIGL Omega Ratio Rank: 64
RIGL Calmar Ratio Rank: 63
RIGL Martin Ratio Rank: 60

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RIGL vs. IAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Integral Ad Science Holding Corp. (IAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RIGL	IAS	Difference
Sharpe ratio Return per unit of total volatility	0.70	—	—
Sortino ratio Return per unit of downside risk	1.55	—	—
Omega ratio Gain probability vs. loss probability	1.19	—	—
Calmar ratio Return relative to maximum drawdown	1.13	—	—
Martin ratio Return relative to average drawdown	2.02	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	RIGL	IAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.70	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.02	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.13	—	—

Drawdowns

Drawdown Indicators

	RIGL	IAS	Difference
Max Drawdown Largest peak-to-trough decline	-99.37%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-50.08%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-57.75%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-85.24%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-86.40%	—	—
Current Drawdown Current decline from peak	-97.19%	—	—
Average Drawdown Average peak-to-trough decline	-90.91%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	27.87%	—	—

Volatility

Volatility by Period

	RIGL	IAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.95%	—	—
Volatility (6M) Calculated over the trailing 6-month period	39.84%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	70.01%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.52%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	82.84%	—	—

Dividends

RIGL vs. IAS - Dividend Comparison

Neither RIGL nor IAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

RIGL vs. IAS - Profitability Comparison

The chart below illustrates the profitability comparison between Rigel Pharmaceuticals, Inc. and Integral Ad Science Holding Corp. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

IAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported a gross profit of 118.81M and revenue of 154.36M. Therefore, the gross margin over that period was 77.0%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

IAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported an operating income of 7.57M and revenue of 154.36M, resulting in an operating margin of 4.9%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.

IAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Integral Ad Science Holding Corp. reported a net income of 7.05M and revenue of 154.36M, resulting in a net margin of 4.6%.

Frequently Asked Questions

Can I hold both RIGL and IAS in my portfolio?

RIGL and IAS have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.